Last reviewed · How we verify
HEC113995PA•H2O tablet
At a glance
| Generic name | HEC113995PA•H2O tablet |
|---|---|
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder (PHASE2, PHASE3)
- The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEC113995PA•H2O tablet CI brief — competitive landscape report
- HEC113995PA•H2O tablet updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI